Fennec Pharmaceuticals Inc. (FENC) |
| 6.25 0.32 (5.4%) 04-14 16:00 |
| Open: | 6.08 |
| High: | 6.315 |
| Low: | 5.93 |
| Volume: | 193,630 |
| Market Cap: | 179(M) |
| PE Ratio: | -18.38 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.34 |
| Resistance 1: | 7.31 |
| Pivot price: | 6.20 |
| Support 1: | 5.65 |
| Support 2: | 4.70 |
| 52w High: | 9.92 |
| 52w Low: | 5.02 |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Financials
| EPS | -0.350 |
| Book Value | 1.030 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.197 |
| Profit Margin (%) | -22.62 |
| Operating Margin (%) | -21.89 |
| Return on Assets (ttm) | -7.3 |
| Return on Equity (ttm) | -69.1 |
Company news
Tue, 07 Apr 2026
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView — Track All Markets
Tue, 07 Apr 2026
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 02 Apr 2026
Fennec (NASDAQ: FENC) CCO gets 120,000 options, 20,679 shares - Stock Titan
Thu, 02 Apr 2026
[Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Thu, 02 Apr 2026
[Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Tue, 31 Mar 2026
24 new Fennec hires get options at $5.77 under Nasdaq rule - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
